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Background/aim: SARS-CoV-2 disease was announced as a pandemic by The World Health Organization in early 2020. It is still threatening
the world population. Here, we aimed to produce hyperimmune sera that contain immunoglobulin G and F(ab')2 fragments sourced from horse
antibodies as an urgent response to the pandemic.
Materials and methods: SARS-CoV-2 was produced and inactivated with three different methods [formaldehyde (FA), formaldehyde, and
binary ethylene amine (FA + BEI), and heat treatment]. After in vitro inactivation control, immunogens were mixed with Freund’s adjuvant,
thereafter horses (n: 2 for FA, 4 for FA + BEI, 2 for heat inactivation) and New Zealand rabbits (n: 6 for FA, 6 for FA + BEI, 6 for heat
inactivation) were immunized four times. Neutralizing antibody levels of the sera were measured at the 4th, 6th, and 8th weeks. When the
antibodies were detected at the peak level, plasma was collected from horses and hyperimmune sera procured after the purification process.
Results: Horses and rabbits produced highly neutralizing antibodies against the SARS-CoV-2 in FA and FA + BEI inactivation groups, foreign
proteins were removed effectively after purification.
Conclusion: This study presents a profitable practice to develop specific antisera in horses against SARS-CoV-2 for emergency and low-cost
response. In further studies, new purification methods can be used to increase the efficiency of the final product.
Key words: Antibody cocktail, F(ab')2, hyperimmune sera, horse sera, immunoglobulin, SARS-CoV-2

1. Introduction
The severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) emerged in late 2019 and has been causing a
pandemic since March 2020. Today, there are 178,207,851
confirmed coronavirus cases, and 3,858,077 deaths reported
all over the world1. Although authorities are trying to decrease
the spreading of the virus by wearing masks, social distancing,
lockdowns, and related regulations, there is still an enormous
increase in exposure. Vaccine development as a decisive
solution is still in progress and although humanity is on the
brink of vaccine production and distribution, many will be
dependent on therapeutics until large numbers of people
could be vaccinated. Still, treatment algorithms are mainly
based on symptom-relieving therapeutics. Different types of
drugs have been used in the treatment of COVID-19 since the

1

start of the pandemic [1]. Inventions on treatment and
prophylaxis are crucially needed [2].
A healthy immune system is essential for rapid recovery
after SARS-CoV-2 exposure. Different types of
immunotherapies procured from patients (convalescent),
animals, or biotechnology sources are implemented as
treatment options as well [3]
Convalescent plasma therapy is a therapeutic and
prophylactic treatment based on using the acellular portion of
a patient’s blood after recovery. This method can be used as a
cure for viral diseases or prevention of disease in individuals
who are in risk groups [4].
There were reports on the promising results of
convalescent plasma therapy in COVID-19 [1,5,6].
Convalescent plasma therapy is related the stage of the
illnesses and the amount of the administered dose. In the early

Worldometers.info (2021). Coronavirus Cases [online]. Website https://www.worldometers.info/coronavirus/ [accessed 18 June 2021].
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stages of infection, convalescent plasma containing polyclonal
neutralizing antibodies may inhibit viral entry as well as
replication [5]. Different doses (200–500 mL/50–80 kg
patient) were administered in to the COVID-19 patients [5,7].
On the other hand, convalescent plasma has some
disadvantages; its production and storage are expensive, it is
dependent on patients who recovered from COVID-19, takes
time to use, needs to be controlled for the existence of other
pathogens, and has limited availability for purification.
Production and standardization of large amounts of
convalescent plasma is very difficult.
Likewise, the animal-originated hyperimmune serum has
also been a treatment choice for diseases. Hyperimmune
serum invention goes back to the 1890s, especially its
application against diphtheria [8]. The hyperimmune serum
was successfully produced in Etlik Veterinary Control Central
Research Institute (Etlik VCCRI) and used in the studies
during 1921–1930 in Turkey [9].
Animal-derived immunoglobulin such as equine sourced
anti-SARS-CoV F(ab´)2 was reported to be effective in cell
culture and murine and the hamster in vivo models [10,11].
Moreover equine sourced F(ab´)2 was reported to protect mice
from Rift Valley fever virus infection [12].
Dixit et al. [13] concluded that equine polyclonal antibody
therapies could also be adapted for widespread and severe
neglected tropical diseases, for example, the viral hemorrhagic
fevers like Crimean-Congo Haemorrhagic Fever, Dengue,
Ebola, and Marburg; bat-transmitted viruses such as Nipah
and Hendra, as well as Lassa virus, West Nile virus, and SARS.
There are studies on neutralizing antibodies against SARSCoV-2 spike protein which has a vital role in SARS-CoV-2
infectivity [4].
A few reports related to COVID-19 animal-sourced
hyperimmune globulins have been published so far [14,15].
Rhesus macaques and golden hamsters treated with
monoclonal antibodies had lower levels of detectable subgenomic viral mRNA in both prophylactic and therapeutic
experiments [2]. Four single or combination monoclonal
COVID-19 antibody treatment third phase human trials have
already started [16].
Equine and ovine sourced hyper-immune sera are already
accepted and authorized as routine therapies including
Europe and North America [17]. Reports have been published
by World Health Organization (WHO) on production,
quality control, and standardization topics [18,19], and
regulations related to both veterinary and human use are
listed in both European and United States Pharmacopeia.
Polyclonal antibodies have been used in rabies prophylaxis,
envenomation, and intoxication. They are promising
treatment options in emerging threats to humans [13].
There are some advantages of animal-sourced
hyperimmune sera compared to convalescent plasma.
Convalescent plasma’s neutralization potential needs to be
tested, monoclonal antibody-based immunotherapeutics are
approved while they are being produced [5]. Hyperimmune
sera are more concentrated and include more antibodies or
F(ab´)2 [20]. Avoidance from transfusion of harmful
coagulation factors and consistent antibody titers are the most
2264

important advantages of hyperimmune plasma therapies over
convalescent plasma therapies [21].
Although human-derived convalescent sera may not be
ready for use initially at the early stages of a pandemic, animal
origin hyperimmune sera can be acquired in 2–4 months in
large amounts with a standardized neutralizing antibody titer.
Due to the production similarities for all diseases, available
veterinarian and human antisera producers can turn out large
amounts in a short time.
Passive antibody therapy is a prophylaxis and treatment
option, moreover, horse-origin immunoserum is controlled,
standardized, cost-effective, and can be produced in large
amounts, and are logistically beneficial compared to
convalescent plasma therapy for low- and middle-income
countries. In this paper, production and important control
points will be handled.
The aim of this study is to develop specific antisera in
horses against SARS-CoV-2 for emergency and low-cost
response.
2. Materials and methods
The Republic of Turkey Ministry of Agriculture and Forestry
also started the response action right after the pandemic
announcement of the WHO and rapidly communicated with
the Ministry of Health according to one health approach and
plans to develop a hyperimmune serum to fight against SARSCoV-2 were made.
2.1. Virus isolation, production in large amounts, and
inactivation
SARS-CoV-2 isolates were obtained from the Health
Institution of Turkey. Eight nasopharyngeal swabs were also
taken from Ankara 29 May State Hospital. Virus isolates from
the Health Institution of Turkey were used as the seed virus
with alternative studies carried out on three of eight swabs as
a contingency plan.
Vero E6 cell culture maintained in Dulbecco's Modified
Eagle's Medium (DMEM, Gibco, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (FBS, Gibco,
Grand Island, NY) was used in virus inoculation, and
incubations were carried out in 37 °C with 5% CO2. First
inoculations were made in 25 cm2 cell culture flasks after
adaptation of the cells in 75 cm2 and 150 cm2 cell culture
flasks. Cells were freeze-thawed after cytopathic effects (CPE)
were observed in each inoculation. Afterward, supernatants
were collected and portioned by centrifugation at 3000 rpm
for 15 min. The accuracy of virus growth after each
inoculation was verified by real-time reverse transcription
polymerase chain reaction (real-time RT-PCR). The volume
of the virus was raised to 2 L. All studies using live viruses were
carried out in the biosafety level 3 laboratory (BSL-3) within
Etlik VCCRI.
The QIAamp Cador pathogen mini kit (Qiagen,
Germany) and Qiagen EZ1 virus mini extraction kit v.2.0
(Qiagen, Germany), and EZ1 Advanced XL workstation was
used with following the manufacturer’s kit protocol for the
extraction of viruses. By the QuantiNova Pathogen + IC Kit
(Qiagen, Germany), real-time RT-PCR was performed by
using the primary probe sets [22]. Samples with amplification
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curves were considered positive. These samples, which were
detected as positive, were confirmed by performing the
whole-genome analysis (unpublished data).
Subsequently, viral suspension with a 106.0–7.0 TCID50/0.1
mL titer was centrifuged and filtered with the intent of largescale antigen production (Millipore, Opticap XL capsule filter,
0.2 µm) and stored at –80°C until inactivation [23]. Then it
was inactivated by treatment with binary ethyleneamine
(Merck, Germany) + formaldehyde 37% (J.T.Baker,
Netherlands), only with FA and heat treatment methods [24].
2.2. BEI + FA inactivation process
Before inactivation, virus suspension pH was adjusted to 7.4
± 0.2 with 0.175 M NaOH (Merck, Germany). After the
temperature of the virus suspension was fixed to 26 °C, 10%
FA was added in a ratio of 1:2000 in the final product. 3% BEI
solution was added and continuously mixed during the
process at 26 °C. For inactivation follow-up, samples were
taken at the first 5 h, 12th, and 24th hours. Sodium thiosulfate
(2%, Merck, Germany) was added to all samples and final
product at the end of the 24th hour for terminating the FA
activity. The final product and samples were stored at –80 °C
until inactivation control.
2.3. FA inactivation process
10% FA solution, adjusted to a final ratio of 1:1000 was mixed
with the virus suspension at a ratio of 1:1. The resulting
mixture was subjected to the inactivation process for 48 h at
37 °C with continuous stirring. Samples were taken at 0, 4th,
8th, 12th, 18th, 24th, 30th, 36th, 42nd, and 48th hours for
inactivation follow-up. Sodium thiosulfate (2% Merck,
Germany) was added to all samples taken for the termination
of FA activity and to the final product collected at the 48th
hour. The final product and samples taken were stored at –80
°C for inactivation control.
2.4. Inactivation by heat treatment
The inactivation process was carried out at 65 °C. Virus
suspension was placed in a 2 L water bath. Virus suspension
and water temperature were observed with calibrated and
sterile thermocouple thermometers (Fluke, Germany). The
first sample was taken when the suspension temperature
reached 65 ± 2 °C and continued every 5 min for 30 min.
Later, the time was increased to 1 h in total, the final product
and samples were taken and stored at –80 °C for inactivation
control.
2.5. Inactivation controls
For BEI + FA inactivation process, two flasks from each
cultivation method were inoculated into 25 cm2 cell culture
bottles by using adsorption and nonadsorption cultivation
methods from the 24th sample. Each cultivation was checked
for the presence of CPE after a 6-day incubation period and
removed to –80 °C. After the freeze-thaw process, blind
passages were carried out in three rounds by centrifugation,
using conventional cultivation methods. Six-well cell plates
were used for the 48th hour of the inactivation process with
FA and the 1st hour of the thermal inactivation process to
investigate the presence of the live virus. The controls
performed with the adsorption cultivation method were

repeated as three rounds of blind passages as described above
after the 6-day incubation period.
2.6. Immunization of the animals
Totally 20 New Zealand rabbits (n: 2 for Control, 6 for
BEI+FA, 6 for FA, 6 for Heat; age: 8–12 month; weight: 3–4
kg) and nine mixed bred horses (n:1 for control, 4 for BEI+FA,
2 for FA, 2 for Heat; age: 4–9; weight: 250–350 kg) were used.
All animals had a detailed clinical health assessment after
quarantine and then they were included in the study. Rabbits
housed in 80 cm × 60 cm × 55 cm metal cages at 22 °C and
had an ad-libitum feed and fresh drinking water. Horses
stayed in 4.5 m × 5 m × 5 m boxes in outdoor temperature and
feed with 2 kg mixed feed, 2 kg hay, and ad-libitum water
without pasture.
Immunization was conducted with one injection in a week
and concluded in 4 weeks in all animals. The first two
injections with an interval of one week, 1 mL complete
Freund's adjuvant (F5881, Sigma-Aldrich, Germany) and 1
mL inactive antigen was used; the next two weeks injections
containing 2 mL of Incomplete Freund's adjuvant (F5506,
Sigma- Alderich, Germany) and 2 mL of inactive antigen was
used. Blood and plasma collections were performed at the 4th,
6th, and 8th weeks from horses to monitor the antibody
response following the injections. Two rabbits were excluded
from the study due to subpar health status in one and age in
the other.
Microneutralization test was performed as described by
[25]. 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640, 1:1280, 1:2560,
1:5120, and 1:10240 of serum/plasma/end product samples
dilutions were subjected to neutralization at 37 °C for 1 h,
mixing with an equal volume of SARS-CoV-2 diluted at 100
TCID50 in duplicate for serum sample and quadruplicate for
plasma samples. The tests were evaluated at the end of the 5th
day under the cell culture microscope. The highest dilution
step preventing the formation of CPE in 50% of the dilution
chambers was accepted as the neutralizing titer. Verification
was done by backward titration for each test. The test was
performed by using two wells per serum sample and four wells
per plasma sample. Results were converted to Log10 and
displayed graphically. Rabbit products were not used for
further steps.
Plasma samples were collected from horses, whose titers
were found suitable at the end of antibody titer controls after
immunization, in a completely closed system with the
plasmapheresis device. Collected plasma (totally 75 L) pooled
and tested for extra zoonotic agents according to the WHO
guideline [18]. After then, to collect F(ab')2 fragments from
pooled sera, the plasma purification process was carried out
according to WHO's protocol with 2% pepsin and 2%–5%
caprylic acid [18].
2.7. Final product control
All tests were conducted according to Immunsera for human
use chapter of European Pharmacopeia 10.0 and related
methods [26]. Impurity controls were done by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) method in commercial laboratories (DFA and Sabancı
University) according to Ng et al. [24]. Samples were loaded
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from the stock into the wells at dilution of 1:1, 1:5, and 1:10 as
shown in Figure 1. In SDS-PAGE analysis, it was aimed to
determine the impurities more clearly by loading a higher
amount of sample. SDS-PAGE analysis carried out under
reducing and nonreducing conditions according to Ng et al.
[24] with protein standard ladder (Precision Plus Protein
Western Blotting Standards, BioRad, Germany) and
according to the kit protocol (FastCas Acrylamide Kit,
BioRad, Germany) as shown in Figures 1–2.
To the samples prepared under nonreducing conditions,
2-mercaptoethanol was not added and the samples were not
boiled. For reducing conditions, 2-mercaptoethanol was
added to the samples and they were boiled. The 90 kD band
of 1:50 dilution in nonreducing gel and 23 kD band of 1:50
dilution in reducing gel were taken as reference and
corrections were made according to the dilutions while
evaluating the bands in different wells together. It was
observed that the amounts of protein bands in the different
wells were consistent after dilution correction.
In vivo pyrogenicity tests were carried out in 1.5 kg, adult,
Albino rabbits according to European Pharmacopeia, by the
Scientific-Technological Application and Research Centre of
Kırıkkale University [26]. This test is based on the evaluation
of the increase in rectal body temperature after intravenous

administration in rabbits, depending on the bacterial
endotoxin content of the final product.
To assess the safety of the product, 1 mL of the final
product was intraperitoneally injected into 22–25 g Swiss
albino mice. A total of three batches, including the control
group, were made using both pure (undiluted) form and 1:3
diluted form as the final product. Mice had ad libutum feed
and water. They were weighed on the 1st, 3rd, 5th, and 7th
days.
The final product was controlled in terms of zoonotic and
horse-borne diseases in Etlik VCCRI according to the WHO
guideline [18]. The protein level of the final product was
calculated by the Doumas method by Leco FP 521 (Leco,
USA) in Ankara Food Control Laboratory [27]. Protein
content was calculated by multiplying the resulting nitrogen
content by 6.25.
2.8. Statistical analysis
Grubb's test was performed to identify outlier results at the
beginning of safety tests. After controlling individual weights
that showed a normal distribution, Levene's test was used to
check the homogeneity of variances. The results were
evaluated by the general linear model with repeated measures
method in terms of time and group difference. The resulting
differences were evaluated against the control group in pure

Figure 1. Lane 1: Protein standard ladder (molecular weight, kD). SDS-PAGE analyses were carried out under nonreducing (Lane 2: 1:1,
Lane 3: 1:5, Lane 4: 1:10) and reducing (Lane 5: 1:5, Lane 6 1:10) conditions.
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Figure 2. Results of 8%–16% SDS-PAGE analysis from final SARS-CoV-2 antiserum product prepared under nonreducing conditions (Lane
1: 1:10; Lane 2: 1:50; Lane 3: Protein standard Ladder; Lane 4: 1:100).

and 1:3 diluted groups by two-way Dunnett's test. The limit of
statistical significance was assumed as p < 0.05. Statistical
analyses were conducted with IBM SPSS (v.21.0).
3. Results
The virus strain (GenBank: MW306666) used in this study
was taken from the Health Institution of Turkey and was
produced and subsequently inactivated in large volumes in
the Etlik VCCRI BSL-3 laboratory.
In the inactivation controls, it was determined that the
inactivation was completed within the specified time in both
BEI + FA and FA inactivation. In the 30th min of the thermal
inactivation process, it was determined that the process was
insufficient since CPE development was detected, and
therefore, an additional 30 min of heat treatment was applied
on cell culture. Following this one-hour inactivation process,
there was no CPE development on cell cultures.
No clinical health problems or adverse effects were
observed throughout the study in horses and rabbits. Horse
body condition score remained constant throughout the study
(between 5–6/9). No feed additive used in this study and the
crude protein content of the rations were 7.1% and 18.4%
respectively, in horses and rabbits.
Serum samples taken from all horses and rabbits at the
beginning of the immunization were checked for the presence

of neutralizing SARS-CoV-2 antibodies and all were found
negative. Neutralizing antibody formation kinetics were
observed following immunization. Antibody responses began
to be detected in horses and rabbits from day 21. Following
the third immunization (28th day), there was 14-fold in
antibody titers of horses as shown in Figure 3. Two of the
horses had the highest titer 4 weeks after the first
immunization, while the other four horses had the highest
titer in the 6th week following immunization. It was found
that high neutralizing antibody titer values were maintained
in six out of eight horses in the 8th week. There was no
difference between BEI + FA and FA inactivation methods in
terms of the rate of increase in antibody levels, but higher
antibody levels were achieved in horses immunized with BEI
+ FA as shown in Figure 3.
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As a result of the inactivation and immunization studies
carried out by our institute, the titer values obtained from
horses varied between 1:640 (= 2.8 log10) and 1:5120 (= 3.7
log10) at the individual level, and the neutralizing antibody
titer value of the product obtained after purification was
determined as 1:1280 (= 3.1 log10).
When the rabbits were evaluated in terms of these
differences, it was determined that they reached the highest
titer values in the 6th week following the fourth immunization
and higher titer values occurred in rabbits immunized with
the antigen inactivated with BEI + FA in accordance with the
values in horses as shown in Figure 4. Antibody response was
not obtained in horses and rabbits immunized by the thermal
inactivation method. In rabbits and horses immunized with
BEI + FA and FA inactivated antigen, mean titer values of
horses were found to be higher than rabbits as shown in
Figure 5. Neutralizing titer amount of BEI + FA group was
higher than FA group (p = 0.05). There was no statistically
significant difference in time-dependent variation of titers
occurring in rabbits and horses (p = 0.09). When the titer
changes were examined based on time, the titer values on the
21st day were found to be statistically different from the other
days (p < 0.05), but no significant change was observed
between the following days.

The titer value obtained at the end of the virus
neutralization test performed after the concentration and
purification process of the plasma collected as 75 L was
determined as 1:1280. It was determined that the final product
obtained in the tests of sterility and extra agent controls was
free from bacterial and extra agents.

Figure 3. Individual neutralizing antibody titers (Log10) of horses in FA and BEI + FA groups in 56 days.
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Figure 4. Individual neutralizing antibody titters (Log10) of rabbits in FA and BEI + FA groups in 56 days.

Figure 5. Horse and rabbit mean neutralizing antibody titers (Log10) of FA and BEI + FA groups in 56 days.

It has been determined that the dominant component in
the antiserum content is F(ab’)2 derived from an
immunoglobulin. Direct mass analysis was performed by
MALDI-TOF for the detection of different proteins in the
final product as shown in Figure 6. The peaks seen in the
analysis show the protein weights of the components. Other
peaks were judged to be contaminating proteins from horse
serum. As a result of the analysis, it was determined that the
dominant component in the antiserum sample was F(ab’)2
originating from an immunoglobulin. Proteomic analysis and
SDS-PAGE analysis support this finding.

When the results of gel analysis and molecular sieve
chromatography performed with the SARS-CoV-2 antiserum
under reducing and nonreducing conditions are interpreted
together with the results of the mass analysis; It has been
determined that 84%–86% of the total protein in the
antiserum consists of various immunoglobulins in the range
of 90–200 kD and 14%–16% of the proteins in the antiserum
are in the range of 10–50 kD. The detected percentages were
consistent with each other in the gel electrophoresis analysis,
molecular sieve chromatography results, and electrophoresis
results with the separated proteins made from the original
undissociated antiserum. It is thought that the band seen
2269
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Figure 6. MALDI-TOF results showed its components with the highest level of F(ab’)2.

around 47 kD in the 1:10 dilution well containing a high
amount of protein in nonreducing gels may be the IgG heavy
chain. In the analysis made with separated proteins, the total
amount of protein bands between 37–50 kD was determined
as 6% and the number of proteins between 10–20 kD was
determined as approximately 6%. It has been found that
protein bands between 10–50 kD can be identified by suitable
methods, e.g., mass spectroscopy or affinity chromatography.
Osmolarity value was determined as 324 mOsm/Kg H2O and
13% nitrogen was calculated by the Doumas method [27].
The first day of the safety test was recorded as day 0. The
mice were then weighed on the 1st, 3rd, 5th, and 7th days and
weight gains were evaluated relative to the control group. The
weight changes in the pure (undiluted) and 1:3 diluted final
products were not found to be statistically significant. It was
observed that the weight gain of the experimental groups were
not different from the control group within the week. In vivo
pyrogenicity test results concluded that the pure undiluted
antiserum sample did not have any pyrogenic effect.
4. Discussion
The emergence of the SARS-CoV-2 has brought many
challenges in terms of health. There is currently no vaccine or
drug therapy known to be effective against this virus. The
disease is kept under control with measures such as early and
rapid diagnosis, quarantine, and follow-up. This epidemic
2270

that started around the world created heavy treatment costs.
For these reasons, a need has arisen for easily accessible and
low-cost treatment options in all healthcare fields. In addition
to convalescent plasma therapy, the importance of which has
increased in recent years, antisera, which have a long history
and are actively used in the treatment of rabies infection, is
being considered an alternative treatment method in SARSCoV-2.
Horses and rabbits were cared for throughout the entire
study, kept free from stress, and with attention to their wellbeing. In the ration of a nonworking horse weighing 250 kg,
literature recommend at least 270 g of crude protein per day
[28,29]. In rabbits, the recommended amount of 14%–17%
crude protein is slightly exceeded [30]. The amount of
antibody increased with the amount of crude protein used in
142 g/day horses and 18% rabbits. It is thought that reporting
the characteristics of the rations used in such studies in more
detail will contribute to future studies.
Among the three different inactivation methods used in
the study, the study in which the highest immune response
was obtained in both animal groups was the method
performed with BEI + FA. There are very few publications
that have performed SARS-CoV-2 inactivation and animal
immunization using both inactivates. For this reason, a
detailed comparison based on other sources could not be
made. However, considering that there may be individual
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differences between animals, this result should be evaluated in
detail with a more controlled observation process.
In the study conducted by Zylberman et al. [14] in
Argentina, the receptor-binding region of the spike protein
belonging to the SARS-CoV-2 was amplified by recombinant
applications and the proteins obtained from the cells were
purified by the affinity chromatography method and used in
horse immunizations. The results obtained indicated that an
antibody titer of 1:10240 was reached in horses and that this
titer was highly preserved at the end of the subsequent plasma
purification processes, so the final product contained
neutralizing antibodies at a titer approximately 50 times
higher than the convalescent plasma. Lu et al. [10], in a study
using live SARS-CoV, reported that up to 1:14210 serum
antibody titer was reached in the 7th week following the first
immunization in horses. Following purification, this titer was
determined to be 1:5120.
As a result of the immunization studies performed with
the inactive SARS-CoV-2 carried out by our institute, the titer
values obtained from horses varied between 1:640–1:5120 at
the individual level, and the neutralizing antibody titer value
of the product obtained after purification was determined as
1:1280. Convalescent plasma titer level is found to be
acceptable at 1:160 by The Food and Agriculture Organization
(FAO), and 1:80 when it is not available.
SARS-CoV-2 inactivated by gamma rays was used to
inoculate horses (n: 10, age: 4–10 years) and highly
neutralizing antibody titers were detected by ELISA and the
purity was checked by SDS-PAGE [31]. The purity of the
antisera was determined to be 99% with a neutralizing titer of
over 20,000 [31]. This study also supports our findings and
promises effective results for neutralizing the SARS-CoV-2 in
vivo.
In order to investigate the effects of receptor binding
domain fragments made by plasmids, after three
immunizations performed with Freud's and incomplete
Freud's adjuvant within two weeks, the product was purified
and it was determined to be 20–100 times more potent like in
our study [32].
In another study, horses were injected with trimetric spike
glycoprotein, a method used in anti-rabbit antisera, and
antibody response was approximately 150 times higher than
antibody convalescent serum in horses [33]. This method
provided higher immunogenic potency than our method.
León et al., [15] injected two groups of three horses each,
with either S1 (anti-S1) or a mixture of S1, N, and SEM mosaic
(anti-Mix) viral recombinant protein, and the maximum antiSARS-CoV-2 polyclonal antibody level (approximately 80
times more than convalescent serum) was reached at the end
of 7 weeks. The results obtained indicated that an antibody
titer of 1:25355 was obtained for anti-Mix in horses.
A similar study against Middle East Respiratory Sendrom
was conducted by Gai et al. [34]. In this study, again VLP was
used, but rodents were used to obtain hyperimmune serum in
the study. The results obtained by these researchers gave
similar results to Schimt et al. [35]. However, at the end of the
challenge tests performed in mice and guinea pigs, it was
emphasized that Fc-dependent antibody mechanisms could

play an important role in this process in addition to virus
neutralization, where the timing of therapeutic
administration is critical.
In order for these antibodies to be used primarily in
human health, it is necessary to purify the antiserum by
removing foreign proteins of horse origin that cause side
effects that can lead to anaphylactic shock. For this, it is
recommended to test with immune-affinity columns in future
studies, but it is thought that costs will also play an important
role in decision-making in these applications. Since the rabbit
model used before horses gives similar results in our study, it
may be very advantageous to work with rabbit models before
horse studies to prevent waste of time, labor force, and
resources.
Monoclonal antibody production is expensive and
requires know-how and equipment. This technique is used for
different diseases so far and is still known as one of the safer
and cost-benefit methods in this field. This process will be one
of the efficient, precise, and safe methods against COVID-19.
There are some limitations in our study. First of all, in an
environment where the borders were closed and access to raw
materials were very difficult, our studies after blood collection
from horses were carried out in a company with veterinary
Good Manufacturing Practices. This situation has raised the
question of whether a product produced in veterinary
facilities can be used for human health. Our study has shown
that in such emergencies, veterinary production sites are
indeed suitable for human health products. As in the case of
current pandemic, organizations such as the WHO, FAO,
and/or World Organization for Animal Health by making
emergency action plans together with their sub-institutes,
documenting and updating them regularly, can eliminate the
confusion of authorization in future emergencies, thus
bringing the world one step closer to gathering under a single
health umbrella. The most important output of this study in
times of such a crisis is that this project, which was organized
in a short time with the contribution of many institutions
related to their subjects, has been completed with one health
approach.
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